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Alterations in lysosomal enzymes of the proximal tubule in gentamicin
nephrotoxicity. Gentamicin accumulates in proximal tubule lysosomes,
increases their number, and changes their structure. An important
lysosomal function is degradation of intracellular proteins. To evaluate
the effect of gentamicin on this lysosomal function, we measured the
activity of the key lysosomal proteinases, cathepsin B and L, in
microdissected Si, S2, and S3 segments of rat proximal tubules by
means of a fluorometric microassay. The cathepsin activities were
decreased in Si and S2 following one and four gentamicin injections of
100 mg/kg body weight. The lysosomal enzyme, acid phosphatase, was
also measured and was not decreased by gentamicin. The urine excre-
tion of cathepsins B and L was decreased after gentamicin. This
excludes an increase in urinary loss of cathepsins as the cause of
decreased tubule activity. Structural changes of the lysosomes per se
were excluded as the factor responsible for the reduced cathepsin
activity by demonstrating increased cathepsin B and L activity in
proximal tubule segments from rats injected with dextran, since dextran
induces an increase in number and size of proximal tubule lysosomes.
In vitro incubation of urine and tubule segments with gentamicin
demonstrated a concentration-dependent reversible inhibition of cathep-
sin B and L. We conclude that gentamicin per se decreased cathepsin B
and L activities in proximal tubule segments as early as 24 hours
following one injection due to either enzyme inhibition or reduced
generation of active intralysosomal cathepsin B and L. Gentamicin
may, therefore, reduce renal protein catabolism by decreasing the
activity of the key proteolytic enzymes, cathepsin B and L. Since
cathepsin B and L are proteolytic activators of other lysosomal en-
zymes, their reduced activity may also decrease the activities of other
lysosomal enzymes.
The aminoglycoside antibiotic, gentamicin, is nephrotoxic in
man and experimental animals [1, 2]. Glomerular filtration is the
major route of excretion [3]. Uptake occurs in the proximal
convoluted tubule predominantly via the luminal cell surface [4,
5]. Gentamicin is incorporated into proximal tubule lysosomes
after attachment to luminal surface receptors and endocytosis
[6—9]. It accumulates in the lysosomes, and the renal cortical
tissue half-life is approximately 100 hours [10, 11]. Morphologic
alterations in gentamicin nephrotoxicity are present predomi-
nantly in the proximal tubule [21. Due to the accumulation in the
proximal tubule lysosomes impaired function of these organ-
elles may be an important mechanism leading to proximal
tubular toxicity [2].
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The lysosomes are generally believed to play a major role in
the breakdown of intracellular proteins [12—15]. Protein degra-
dation by the lysosomal system involves sequestration of intra-
cellular proteins in autophagic vacuoles, fusion of these vacu-
oles with primary lysosomes, and degradation of proteins
within the lysosomes by proteases. Cathepsins B and L are
highly active lysosomal proteases. It has been shown that
inhibition of these proteases also inhibits the intracellular
protein degradation by up to 70% [12—151. In order to evaluate
the effect of gentamicin on this important aspect of lysosomal
function, we measured cathepsin B and L activities in micro-
dissected segments of the proximal tubule from gentamicin
injected rats. Measurements of the lysosomal marker enzyme,
acid phosphatase, served as a control for the selectivity of the
induced changes. Segmental analysis of enzyme activities was
deemed essential since gentamicin uptake may be different
between the consecutive segments of the proximal tubule [6, 7].
To gain further insight into the mechanism of cathepsin
changes, the urinary excretion of these enzymes and the in vitro
effect of gentamicin on cathepsins were both studied. To
account for effects that were probably induced by enlargement
of lysosomes observed in gentamicin nephrotoxicity, cathepsin
activity was also measured in tubules from rats injected with
dextran, that also induces similiar enlargement of lysosomes.
Methods
Female Sprague-Dawley rats weighing 165 to 240 g were
studied. The animals had free access to standard rat chow
(Altromin, Spezialfutter GmbH, 4937 Lage, Germany) and tap
water.
Experimental protocols
Gentamicin injection. Seven rats received one subcutaneous
injection of gentamicin (Byk-Essex Pharma, München, Ger-
many) at a dose of 100 mg/kg body weight, and 13 rats received
four s.c. injections of gentamicin at 24 hour intervals. Eleven
control rats received four s.c. injections of vehicle only. An
additional 16 rats received four s.c. injections of the same dose
of gentamicin. These rats were kept continuously in metabolic
cages, the urine was collected, and urinary cathepsin activities
and creatinine clearance were measured daily. Blood was
collected by retrobulbar puncture.
Dextran injection. One gram of dextran (Dextran 20, mean
molecular wt of 20,000 daltons, Pharmacia, Uppsala, Sweden)
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was dissolved in 4 ml of isotonic saline. Six rats received eight
i.p. injections of 1 g of dextran at 12 hour intervals.
In all animals in the gentamicin and dextran groups, the
enzyme activities were measured 24 hours following the last
injection. Twenty-four hours prior to sacrifice all rats were kept
in metabolic cages. Urine was collected and creatinine clear-
ance and urinary protein content were measured. The rats were
sacrificed by stunning and dislocation of the neck. Blood was
collected by cardiac puncture.
Determination of creatinine and protein. Creatinine in urine
and plasma was determined using a modified Jaffes picric acid
method (Beckman Creatinine Analyzer 2, Beckman Instru-
ments, Fullerton, California, USA). Protein in urine was deter-
mined by Lowry's method [161.
Determination of gentamicin in kidney cortex. The concen-
tration of gentamicin in the kidney cortex was determined in six
rats following one injection and in six rats following four
injections of gentamicin at a dose of 100 mg/kg of body weight.
Tissue samples were prepared using an adaptation of the
method of Kornguth and Kunin [171. Previously weighed sam-
ples of kidney cortex (213 to 306 mg) were repeatedly frozen in
dry ice and thawed. The samples were homogenized in 6 ml of
a 10 mmolar phosphate buffer, pH 7.4, using a cooled Sorvall
Omni-Mixer four times for four minutes at 50,000 RPM. During
the third and the fourth steps, the homogenate was acidified
with 4 ml trichioroacetic acid to obtain protein denaturation.
After centrifugation (x 1200 g for 20 mm), the supernatant was
titrated to pH 6.5 to 7.5 with 10% sodium hydroxide. Gentami-
cm was measured by fluorescence polarization immunoassay
using a commercially available system (TDx Unit Dose System
Gentamicin, Abbott Health Care Products, mc, Abbott Park,
Illinois, USA).
Determination of cathepsin B and L activity in microdis-
sected segments of rat nephron. The activities of cathepsins B
and L in microdissected nephron segments were measured by
an ultramicroassay developed recently [18]. We used Z-phenyl-
alanyl-arginine-7-amido-4-methylcoumarin (Z-Phe-Arg-NMec)
as the substrate for cathepsin B and L together. The enzymes
cleave the substrate and release the free 7-amino-4-methyl-
coumarin group (NMec) which is highly fluorescent and can be
measured at very low concentrations in small fluid volumes.
The substrate is specific for cathepsin B and L [181.
Solutions. All solutions were prepared from glass distilled
water to minimize the backround fluorescence. All chemicals
were reagent grade. The dissection solution contained (in
mmol/iiter): NaCI, 136; KCI, 3; K2HPO4, 1; MgSO4, 1.2; CaCI2,
2; sodium lactate, 4; sodium citrate, 1; L-alanine, 6; and
glucose, 5.5. The collagenase solution was identical to the
dissection solution except for the addition of 0.1% collagenase
(Sigma, Type I). The rinsing solution contained (in mmol/liter):
Na2HPO4, 11.5; KH2PO4, 55.2; and EDTA, 4. The pH was 6.0
and the osmolality was 141 mOsmol/kg H20. The preincubation
solution was the same as the rinsing solution but, in addition
contained 0.2% Triton X 100 (Sigma) and 0.05% bovine serum
albumin (Sigma). The substrate, Z-Phen-Arg-NMec, was ob-
tained from Bachem Feinchemikalien, Bubendorf, Switzerland.
A 10 mmolar stock solution of the substrate was prepared in
DMSO (dimethyl suiphoxide). The stock solution was diluted
daily to a 1 mmolar solution with 0.1% Brij 35 solution (Sigma).
To this final substrate solution, 8 mmol/liter cysteine were
added immediately before use. The stop solution contained 100
mmollliter iodoacetate in a buffer containing 30 mmollliter
sodium acetate and 70 mmol/liter acetic acid. The pH was 4.75.
For preparation of standard curves, the reaction product NMec
was obtained from Bachem Feinchemikalien, Bubendorf, Swit-
zerland.
Collagenase treatment. Immediately after sacrifice the left
kidney was removed rapidly and immersed in ice-cold dissec-
tion solution. Twenty ml of the same solution were perfused
through the renal artery to remove all blood remaining in the
kidney. This was followed by perfusion of 10 ml of ice-cold
collagenase solution. Pieces of tissue were then sliced along the
corticomedullary axis and incubated for 30 minutes in the same
collagenase solution gassed with 100% oxygen in a shaking
water bath at 37°C. The tissue was then rinsed with the
dissection solution and maintained on ice until dissection.
Collagenase was used to facilitate dissection of the proximal
tubule segments. The collagenase treatment did not alter ca-
thepsin activities significantly, as demonstrated recently [18].
Microdissection. Individual tubules were dissected as de-
scribed previously [18]. Based on morphology and function
three segments of the proximal tubule, Si, S2, and S3 can be
identified and dissected separately. In the present study Si was
identified as the first three mm of the proximal tubule attached
to the glomerulus, while S2 included the last mm of the pars
convoluta (S2c) and the first mm of the pars recta (S2r), and S3
was identified as the last mm of the pars recta immediately
before the transition into the thin descending limb of Henle. The
dissected segments were straightened and the length was mea-
sured using an eyepiece micrometer. The length varied from 200
to 1000 tm. Each segment was then transferred into a second
dissection dish with the rinsing solution. After 10 seconds the
segments were transferred with a 2 pi volumetric pipette into a
reaction vial containing 24 tl of preincubation solution. The
vials were sealed and frozen in dry ice for ten mm before
preincubation was initiated.
In each rat between three and ten samples of each segment
were dissected and analyzed.
Incubation. The samples were preincubated for ten minutes
in a shaking water bath at 37°C. The preincubation in the
hypoosmolar preincubation solution lysed the tubules com-
pletely. Next, the vials were kept on ice while 25 d of substrate
solution were added. At this point the samples were incubated
for 60 minutes in a shaking water bath at 37°C. The enzyme
reaction was stopped by placing the vials on ice and adding 500
d of stop solution. To evaluate the background fluorescence
due to either substrate contamination with reaction product or
spontaneous hydrolysis of the substrate during incubation, vials
containing 25 jd of preincubation solution and 25 d of substrate
solution without nephron segments were treated identically. A
standard curve was measured with each experiment.
Measurement of fluorescence. The fluorescence was mea-
sured with a Turner Model III fluorometer (Turner Assoc., Palo
Alto, California, USA) using the reaction vial as a cuvette. The
sample was excited at 365 nm (Corning filter CS-7-83) and the
emission was recorded at 450 nm (Corning filter CS-3-72). The
fluorometer reading was adjusted to zero with glass distilled
water. Enzyme activity was calculated as pmol of NMec
generated per mm tubule length per mm incubation time from
the standard curve using NMec. The enzyme assay was linear
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with respect to incubation time and tubule length as described
previously [181.
Determination of acid phosphatase activity in microdissected
tubule segments. The activity of acid phosphatase in proximal
tubule segments was measured utilizing 4-methylumbelliferyl
phosphate (4-MUP, Sigma) as a substrate, according to the
method previously published [19]. Acid phosphatase cleaves
4-MUP and releases free 4-methyl-umbelliferone (4-MU) which
is highly fluorescent. The method is identical to the cathepsin
determination, including tissue preparation, microdissection,
preincubation, incubation, adding of stop solution and measure-
ment of fluorescence. However, all solutions were different,
except the dissection and collagenase solutions. The rinsing
solution contained 0.2 M sodium acetate-acetic acid buffer and
2 mmol/liter EDTA, and had a pH of 4.8 and an osmolality of
158 mOsmlkg H20. The substrate solution was prepared from
the rinsing solution by adding 1 mmol/liter 4-MUP. The prein-
cubation solution was prepared from rinsing solution by adding
0.2% Triton X-l00 and 0.05% bovine serum albumin. The stop
solution contained 0.5 mol/liter of glycine adjusted to pH 10.4
with 5 N NaOH. A standard curve was measured with each
experiment. The enzyme activity was expressed in pmol reac-
tion product, 4-MU, liberated per mm incubation time per mm
tubule length. The assay was specific for acid phosphatase, and
was linear with respect to incubation time and tubule length
[20].
Determination of cathepsin B and L in plasma and urine. The
enzyme activities were measured by a fluorometric assay uti-
lizing Z-Phe-Arg-NMec as a substrate. The urine was centri-
fuged for 10 minutes at 5,000 RPM. Five ml of the supernatant
were dialyzed for 24 hours in the cold against two changes of a
solution composed of potassium citrate, 30 mmol/liter; NaCI,
100 mmol/liter and 0.1% Triton X, pH 6.0. Dialysis tubing made
of regenerated cellulose with an exclusion limit of 8000 to 15000
daltons was employed (Visking Dialysis Tubing, Type 27/32,
Serva Feinbiochemica, Heidelberg, Germany). The volume of
the bath solution was 200 ml. In urine samples from animals
obtained two, three, and four days following gentamicin injec-
tion, cathepsin activity was measured prior to and following
dialysis. In preliminary experiments 1 ml of plasma was dialzed
for 24 hours, and the cathepsin activities prior to and following
dialysis were identical. Hence, determination of cathepsin B
and L in plasma during the experiments was performed without
dialysis. Plasma and urine were appropriately diluted. Two jd
of the sample were added to 25 d of a preincubation solution
containing (in mmollliter) Na2HPO4, 11.5 (A component);
KH2PO4 (B component), 55.2; EDTA, 4; and 0.2% Triton X.
The pH was 6.0. The vials containing the samples were kept on
ice and 25 d of substrate solution were added. A 10 m stock
solution of Z-Phe-Arg-NMec was prepared in dimethyl sulphox-
ide (DMSO, Sigma). This stock solution was diluted daily to a
1 mM solution with 0.1% Brij 35 solution (Sigma). To this final
substrate solution, 8 mmol/liter cysteine was added immedi-
ately before use. The samples were incubated for 15 minutes in
a shaking water bath at 37°C. The enzyme reaction was stopped
by placing the vials on ice and adding 500 d stop solution. The
stop solution contained 100 mmol/liter iodoacetate in a buffer
consisting of 30 mmol/liter sodium acetate and 70 mmol/liter
acetic acid. The pH was 4.75. The fluorescence was determined
as described above. The enzyme activity in plasma was ex-
pressed in nmol of the reaction product, NMec, released per
hour and per ml of plasma. The activity in urine was expressed
in nmol NMec released per hr per mol of creatinine in urine.
The linearity of the assay with incubation time was evaluated
by incubating two d samples of the same urine or of the same
plasma for different times between 5 and 30 minutes. The
linearity with enzyme activity was evaluated by incubating two
pi aliquots of the same urine or of the same plasma for 15
minutes that were differently diluted.
In vitro experiments. The in vitro effects of gentamicin on
cathepsin B and L in urine and proximal tubules were studied
by measuring cathepsin activities following preincubation with
gentamicin. Urine samples from eight control rats were prein-
cubated with 0.6, 1.0, and 5.0 mg/ml of gentamicin for five
minutes. To verify the reversibility of the effect, urine samples
preincubated with 5 mg/mI of gentamicin were dialyzed for 24 h.
The effect of gentamicin on proximal tubule cathepsin activity
was evaluated by incubating 51 segments of four control rats
with 0.3, 0.6, 1.0, and 5.0 mglml of gentamicin. In preliminary
experiments it was demonstrated that 5 mg/mI of gentamicin
decreased the pH of the incubation solution from 6 to pH 5.1.
The pH of 6.0 was maintained by changing slightly the concen-
tration of the A and B component of the phosphate buffer in the
preincubation solution. Standard curves were measured with
each gentamicin concentration. The values were not different
from normal standard curves without gentamicin. Hence, gen-
tamicin did not interfere with the assay.
Statistics
Data are given as mean SD. Differences were evaluated by
Student's f-test. Pre- and post-dialysis urine cathepsin activities
were compared by Student's f-test for paired values. Multiple
comparisons between urine and plasma cathepsin on different
days were calculated by analysis of variance and by f-test with
Bonferroni correction, and P values <0.05 were regarded as
significant. The significance of correlations was evaluated by
linear regression analysis.
Results
Physiological data
The data describing the animal population under study are
presented in Table 1. No changes were observed after one
gentamicin injection. Four gentamicin injections were accom-
panied by an increase in urine volume (P < 0.05). The creati-
nine clearance was decreased to 79% of the control value (P <
0.05). Following eight injections with dextran the urine volume
was increased (P < 0.05), while the creatinine clearance re-
mained unchanged.
Cathepsin B and L activities in proximal tubule segments
In control rats the highest activities were found in the Sl
segments (Fig. 1). The S3 segments had very low activities
amounting to only 10% of the activities in SI segments. Fol-
lowing one gentamicin injection the cathepsin B and L activity
was decreased in the third mm of Sl (P < 0.05), in S2c (P <
0.02) and in S2r (P < 0.01). After four injections the enzyme
activities were reduced in the third mm of Sl (P < 0.01), in S2c
(P <0,02), and in S2r (P < 0.005). The cathepsin activities in S3
segments remained unaltered by gentamicin. Dextran injections
Ca
th
ep
sin
 B 
a
n
d 
[ac
tiv
ity
 
N
M
ec
, p
m
ot
 rn
/n
 
m
m
 
—
 
W
 
01
 
0 
0 
0 
0 
0 
0 
0 
0 
p 
I 
I 
-
 
I 
I 
+
 
642 Olbricht et a!: Gentamicin and renal proteolytic activity
Table 1. Functional parameters of rats injected with gentamicin, 100 mg/kg body weight, or with dextran, 8 x 1 g
Urine Creatinine Urine
Body wt volume clearance protein
Group N
—
g
—_______
ml/24 hr ml/min/100 g mg/24 hr
Control Ii 185 9 11 3 0.71 0.09 4.3 l.
Gentamicin, I X 7 186 13 10 3 0.68 0.12 4.6 l.
Gentamicin, 4 x 13 182 15 26 l2 0.55 0.lla 5.5 l.(
Dextran 6 217 20 17 6 0.68 0.12 4.1 0.(
Values are mean SD. Creatinine clearance is calculated per 100 g body weight.
a P < 0.05 vs. control
Acid phosphatase activities
Fig. 1. CathepsinB and L activity in
microdissected segments of proximal tubules
from gentamicin-injected rats. Abbreviations are:
SI, the first three mm attached to the glomerulus:
S2c, the last mm of the pars convoluta. S2r: the
first mm of the pars recta; S3, the last mm of the
pars recta prior to the thin descending limb of
Henle. Open bars represent values from control
rats (N = 11). Hatched bars show data from rats
following one injection of gentamicin (N = 7).
Solid bars represent activities from rats after four
injections of gentamicin (N = 13). The values are
mean SD. Asterisks indicate P < 0.05 vs.
control values.
The values of acid phosphatase activity are depicted in Figure
3. Gentamicin did not change the enzyme activities in the
proximal tubule segments. Dextran injections were accompa-
nied by a significant increase in acid phosphatase activity in the
first mm of Si and in S2c(P < 0.05).
Cathepsin B and L in plasma and urine
The enzyme assay developed for determination of cathepsin
B and L in urine and plasma showed a linear correlation with
respect to incubation time and urine and plasma volume,
respectively (Figs. 4 and 5 for urine, plasma data not depicted).
The enzyme activity in plasma was 404 149 nmol/hr/ml during
the control period 24 hour prior to gentamicin injection (Fig. 6).
No significant changes were observed following gentamicin
injection. The urine excretion of cathepsin B and L in the
control period was 623 274 nmol/hr/mol creatinine (Fig. 6).
This value remained unchanged during the first day following
gentamicin injection. The enzyme activity dropped to 201 91
nmolThr/mol creatinine on the second day and remained low
on the third and fourth day (P < 0,05, respectively, vs. the
Fig. 2. Cathepsin B and L activity in microdissected segments o
proximal tubules from dext ran-injected rats. Abbreviations are: Si, th
first two mm attached to the glomerulus; S2c, the last mm of the par
convoluta; S3, the last mm of the pars recta immediately prior to th
thin descending limb of Henle. Open bars represent values from contro
rats (N II). Shaded bars represent activities from rats after eigh
injections of dextran (N = 6). The values are mean SD. Asterisk
indicate P < 0.05 vs. control values.
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were accompanied by significant increases in cathepsin B and L
activities in all dissected proximal tubule segments (Fig. 2). The
P values versus control were: Si, 1 mm, <0.05; Si, 2 mm, <
0.005; S2c, <0.001; S3, <0.001.
*
*
S1lmm 2mm S,c S2r S3
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10
11 ftlftIn.m.
S1lmm 2mm S2c S2r
Fig. 3. Acid phosphatase activity in microdissected proximal tubule
segments from rats after injection of gentamicin or dextran. Abbrevi-
ations are: Si, the first two mm attached to the glomerulus; S2c, the last
mm of the pars convoluta; 52r, the first mm of the pars recta. Open bars
represent values from control rats (N = 10). Hatched bars show data
from rats following four injections of gentamicin (N = 8). Solid bars
represent activities from rats after eight injections of dextran (N = 6).
The values are mean SD. Asterisks indicate P < 0.05 vs. control
values. n.m., not measured.
Fig. 5. Assay of cathepsin B and L activity in urine. Relationship
between liberated reaction product (NMec) and incubated urine vol-
ume. Each symbol represents values from one rat. The correlation
coefficient was 0.99 for both urines.
Gentamicin in kidney cortex
0
Incubation time, minutes
Fig. 4. Assay of cathepsin B and L in urine. Linearity of liberated
reaction product (NMec) with time of incubation. Two d of identical
urine were incubated for different time intervals. Each symbol repre-
sents values from one rat. The correlation coefficient for both urines is
0.99.
control period). The creatinine clearance in these animals
remained constant during the experimental period (Fig. 6).
Urine cathepsin activities from rats three and four days
following gentamicin injection were measured before and after
24 hours of dialysis (Fig. 7). No changes in enzyme activities
were observed.
In vitro experiments
In vitro incubation of proximal tubule Si segments and of
urine with gentamicin showed a concentration dependent inhi-
bition of cathepsin B and L activity (Fig. 8). For instance, 5
mg/mi of gentamicin reduced the tubular enzyme activity to 15
6% and the urine enzyme activity to 33 8% of the control
value (P < 0.001, respectively). The inhibition of cathepsin B
After one injection of gentamicin at a dose of 100 mg/kg body
weight, the concentration of gentamicin in the kidney cortex
was 313 70 g/g wet weight (N = 6). After four injections at
24 hour intervals, the concentration amounted to 1288 200
j.g/g wet weight (N = 6).
Discussion
Gentamicin injections were accompanied by reduction of
cathepsin B and L activities in the third mm of Si segments and
in both S2 segments of the proximal tubule as early as 24 hours
following the first injection, while the control values of cathep-
sin were similar to previously reported data [18]. The pattern of
cathepsin inhibition is in good agreement with results from
autoradiographic studies of gentamicin uptake by the rat prox-
imal tubule [6, 7], showing significant accumulation of gentami-
cm only in Si and S2 segments. A slight decrease in cathepsin
B activity was described recently in homogenates of kidney
cortex at six days following daily gentamicin injections of 50
mg/kg [20]. Comparisons are difficult to make since the applied
substrate used for cathepsin B was less specific [21], the
gentamicin dose was lower, and our analysis was far more
sensitive due to the determination of cathepsin activities in
single segments.
Factors that must be considered in the interpretation of our
data, in addition to gentamicin accumulation, include changes
in the level of proteinuria, altered structure of the lysosomes,
necrosis of proximal tubule cells, and increased exocytosis of
lysosomes containing cathepsins. The level of urinary protein
excretion affects cathepsin activities in the proximal tubule [18].
However, such a mechanism is unlikely in the present experi-
ments since protein excretion remained unchanged following
gentamicin injection. Within 48 hours following gentamicin
administration an increase in the number and size of lysosomes
which contain both myeloid bodies and amorphous material is
observed in the proximal tubule [22—241. These changes per se
have to be considered as causal factors for the observed
decrease in cathepsin activity. To evaluate this possibility we
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Fig. 6. Cathepsin B andL activities in plasma and urine. Open bars are
values from rats 24 hours prior to gentamicin injection. Cross hatched
bars represent data from the rats following one, two, three, and four
injections of gentamicin. N = 12. The values are means SD. Asterisks
indicate P < 0.05 vs. preinjection value. The lower panel shows the
creatinine clearance of the same animals.
measured cathepsin activity in dextran-injected rats. Dextran is
filtered by the glomerulus, is partly reabsorbed by proximal
tubule cells, and induces an increase in the size and number of
lysosomes [25]. In contrast to gentamicin, dextran induced an
increase in proximal tubule cathepsin activities. Therefore, it
appears unlikely that altered structure of lysosomes per Se is the
primary event leading to decreased cathepsin activity, although
admittedly the changes in lysosomal ultrastructure caused by
gentamicin are different from those following injection of dex-
tran.
Following the initial lysosomal alterations the morphologic
changes in proximal tubules progress to frank cellular necrosis
[2, 221. The observed decrease in cathepsin B and L activity
could be related to cell necrosis. However, the reduction of
cathepsin activities as early as 24 hours following a single
injection of gentamicin argues strongly against necrosis as a
causal factor since overt cell necrosis has not been described in
the proximal tubule at that early time. Furthermore, a loss of
tubular cathepsins by cell necrosis as well as a loss by an
increased rate of exocytosis of lysosomes containing cathepsins
Concentration of gentamicin, mg/mi
fig. 8. In vitro inhibition of cathepsin B and L activity by gentamicin.
Triangles represent urine cathepsin activities from eight rats. Squares
represent enzyme activities in Si segments from four rats. In each rat
three to five segments were analyzed for each gentamicin concentra-
tion. Values are mean SD.
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Fig. 7. Cathepsin B and L activities in urine of 12 rats after four
gentamicin injections. Values were measured immediately prior to and
after 24 hours of dialysis. The pre-dialysis and post-dialysis values were
not different (P > 0.05). The enzyme activity is expressed in nmol
reaction product (NMec) released per hour incubation per d.
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seems unlikely since the urine cathepsin excretion was actually
reduced in rats following gentamicin injection. Increased urine
excretion of cathepsins would be a prerequisite for both mech-
anisms. An additional argument against cell necrosis and exo-
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Fig. 9. Reversible inhibition of urine cathepsin B and L activity by
gentamicin. Urine samp'es from eight control rats were analyzed
without dialysis (A), after one hour incubation with 5 mg/mI of genta-
micin (B), and after incubation with gentamicin followed by 24 hours of
dialysis (C). Pre- and post-dialysis values were not different. The
inhibition of cathepsin B and L activity by gentamicin was significant (P
<0.001 vs. pre- and post-dialysis).
cytosis is the finding of an unchanged acid phosphatase activity
following gentamicin. Both mechanisms should lead to reduced
acid phosphatase activity, Therefore, the data support the
interpretation that gentamicin itself induced the decrease in
cathepsin B and L activities.
The finding of a similar reduction in tubular cathepsin activ-
ities following one and four injections (Fig. 1) in spite of a
fourfold increase in gentamicin concentration in the kidney
cortex does not argue against a causal relationship between
gentamicin accumulation and cathepsin reduction. It is conceiv-
able that the concentration following one injection was suffi-
cient for a maximum inhibitory effect, and an increase in
gentamicin concentration may not further decrease cathepsin
activities. It is also conceivable that the intralysosomal concen-
tration of gentamicin was similiar on the first and the fourth day
following gentamicin injection, since the increase in kidney
cortex concentration could be mainly due to an increase in the
number and size of the lysosomes in the proximal tubules.
Gentamicin may reduce cathepsin B and L activity by two
mechanisms, enzyme inhibition and decreased generation of
active intralysosomal enzyme. Direct enzyme inhibition is the
less likely mechanism. Although we found in vitro inhibition of
cathepsin B and L activity in tubule segments as well as in
urine, this inhibition was reversible by 24 hours of dialysis. The
assay procedure for cathepsins in tubule segments included a
dilution step of approximately 1:5000, since one tubule segment
with about 0.01 d volume was dissolved in 50 pi incubation
solution. This dilution should be sufficient to abolish all revers-
ible inhibition. Hence, reversible inhibition of cathepsin B and
L activity, as demonstrated for urine cathepsin, is unlikely to
explain the reduced enzyme activities. On the other hand,
direct inhibition may be present in vivo, and the true in vivo
cathepsin B and L activity could be considerably lower than
measured in the present study. This may be of functional
importance.
The likely explanation for the reduced cathepsin activity is an
inhibition in the generation of active intralysosomal cathepsins
by gentamicin. The process of generation of active lysosomal
enzymes involves biosynthesis of precursors on membrane-
bound polysomes, modifications at the Golgi, and transport to
and uptake into the lysosomes where proteolytic processing
generates mature active enzymes [26, 27]. It is possible that one
or more of these steps may be inhibited by gentamicin. For
instance, inhibition of microsomal protein synthesis in the
kidney cortex has been described two days following gentami-
cm injection [28]. It is conceivable, however, that intralysosom-
al proteolytic activation or precursor uptake into lysosomes or
both are also inhibited by gentamicin.
The functional relevance of decreased cathepsin activities
caIys may be twofold. The inhibition of cathepsins reduced cellular
protein degradation in other organs by up to 70% [12—15].
Hence, a decrease in proximal tubule protein catabolism by
gentamicin seems likely. This hypothesis is supported by the
finding that the degradation of low molecular weight proteins
which are filtered by the glomerulus and reabsorbed by the
proximal tubule, was reduced in kidney cortex from rats
injected with gentamicin [29]. Degradation to amino acids
occurs in the lysosomes by proteases including cathepsin B and
L. Furthermore, cathepsin B and L, as well as other cysteine-
proteinases are involved in the proteolytic activation of lyso-
somal enzyme precursors [26, 27], and a decrease in cathepsin
activity may lead to decreased activities of other lysosomal
enzymes. Therefore, the accumulation of phospholipids in renal
cortex following gentamicin administration and the appearance
of myeloid bodies in proximal tubule lysosomes, which have
been attributed to reduced activities of phospholipases and
sphingomyelinase [20, 30], may be the indirect result of cathep-
sin inhibition by gentamicin.
The link between renal functional deterioration in gentamicin
nephrotoxicity, reduced protein catabolism and reduced activ-
ity of other lysosomal enzymes remains to be determined. It
may be similiar to lysosomal storage disease where the reduced
activity of one lysosomal enzyme causes serious morbidity.
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